Johnson & Johnson Shares Outstanding 2010-2022 | JNJ

Johnson & Johnson shares outstanding history from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Johnson & Johnson shares outstanding for the quarter ending March 31, 2022 were 2.667B, a 0.23% decline year-over-year.
  • Johnson & Johnson 2021 shares outstanding were 2.674B, a 0.12% increase from 2020.
  • Johnson & Johnson 2020 shares outstanding were 2.671B, a 0.51% decline from 2019.
  • Johnson & Johnson 2019 shares outstanding were 2.684B, a 1.63% decline from 2018.
Johnson & Johnson Annual Shares Outstanding
(Millions of Shares)
2021 2,674
2020 2,671
2019 2,684
2018 2,729
2017 2,745
2016 2,789
2015 2,813
2014 2,864
2013 2,877
2012 2,813
2011 2,775
2010 2,789
2009 2,789
Johnson & Johnson Quarterly Shares Outstanding
(Millions of Shares)
2022-03-31 2,667
2021-12-31 2,674
2021-09-30 2,675
2021-06-30 2,672
2021-03-31 2,673
2020-12-31 2,671
2020-09-30 2,669
2020-06-30 2,666
2020-03-31 2,671
2019-12-31 2,684
2019-09-30 2,670
2019-06-30 2,692
2019-03-31 2,699
2018-12-31 2,729
2018-09-30 2,728
2018-06-30 2,721
2018-03-31 2,732
2017-12-31 2,745
2017-09-30 2,738
2017-06-30 2,742
2017-03-31 2,755
2016-12-31 2,789
2016-09-30 2,785
2016-06-30 2,794
2016-03-31 2,804
2015-12-31 2,813
2015-09-30 2,807
2015-06-30 2,812
2015-03-31 2,826
2014-12-31 2,864
2014-09-30 2,864
2014-06-30 2,874
2014-03-31 2,875
2013-12-31 2,877
2013-09-30 2,881
2013-06-30 2,893
2013-03-31 2,859
2012-12-31 2,813
2012-09-30 2,818
2012-06-30 2,798
2012-03-31 2,775
2011-12-31 2,775
2011-09-30 2,778
2011-06-30 2,781
2011-03-31 2,773
2010-12-31 2,789
2010-09-30 2,786
2010-06-30 2,796
2010-03-31 2,797
2009-12-31 2,789
2009-09-30 2,793
2009-06-30 2,782
2009-03-31 2,790
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $465.705B $93.775B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $294.404B 10.27
Eli Lilly (LLY) United States $283.955B 33.50
AbbVie (ABBV) United States $266.851B 11.70
Merck (MRK) United States $236.570B 13.36
Novartis AG (NVS) Switzerland $200.009B 14.40
GlaxoSmithKline (GSK) United Kingdom $113.161B 13.21
Novo Nordisk (NVO) Denmark $0.000B 32.07